Multinational phase 3 trial of first-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer: final outcomes from CheckMate 227

The phase 3 CheckMate 227 Part 1 study demonstrated survival benefit with first-line nivolumab plus ipilimumab versus chemotherapy among patients with metastatic non-small cell lung cancer (mNSCLC). The final efficacy and safety results from the study have now been published. Adults with mNSCLC and no sensitizing EGFR/ALK mutations were stratified by tumor PD-L1 ≥1% (n=1189) or <1% (n=550) and randomized to nivolumab plus ipilumab, nivolumab alone (PD-L1 ≥ 1% only), nivolumab plus chemotherapy (PD-L1 <1% only), or chemotherapy alone. At a minimum follow-up of 91.9 months, nivolumab plus ipilimumab continued to demonstrate long-term overall survival (OS) benefit versus chemotherapy in patients with PD-L1 ≥1% (at 7 years OS rates 19% versus 10%; HR 0.78; 95% CI 0.67-0.91) or PD-L1<1% (14% versus 4%; 0.64; 0.51-0.79). Rates of ongoing response at 7 years were higher with nivolumab plus ipilimumab than chemotherapy among responders with PD-L1 ≥ 1% (25% versus 3%) or PD-L1 <1% (20% versus 3%). Clinical benefit with nivolumab plus ipilimumab was observed across most patient subgroups. No new safety signals were observed. The authors conclude that this final analysis from CheckMate 227 confirms that nivolumab plus ipilimumab confers long-term durable clinical benefit versus chemotherapy in patients with mNSCLC across both the tumor PD-L1 ≥1% and PD-L1 <1% populations (graphical abstract).